行情

GNCA

GNCA

Genocea
NASDAQ

实时行情|Nasdaq Last Sale

3.580
+0.140
+4.07%
盘后: 3.500 -0.08 -2.23% 16:00 09/13 EDT
开盘
3.440
昨收
3.440
最高
3.620
最低
3.440
成交量
20.07万
成交额
--
52周最高
11.28
52周最低
2.240
市值
9,361.59万
市盈率(TTM)
-1.5306
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GNCA 新闻

  • Genocea to Present at September Healthcare Conferences
  • GlobeNewswire.08/30 13:00
  • 10 Biopharmaceutical Companies Trying To Cure Cancer
  • Benzinga.08/24 18:46
  • 10 Biopharmaceutical Companies Trying To Cure Cancer
  • Benzinga.08/24 17:46
  • Edited Transcript of GNCA earnings conference call or presentation 25-Jul-19 12:30pm GMT
  • Thomson Reuters StreetEvents.08/05 15:07

更多

所属板块

生物技术和医学研究
+0.20%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

GNCA 简况

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor.
展开

Webull提供Genocea Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。